Savara jump­ing to the NYSE in re­verse merg­er with zom­bie biotech Mast

Af­ter rais­ing $20 mil­lion and lay­ing out plans for a Phase III piv­otal tri­al of a re­for­mu­lat­ed an­tibi­ot­ic, Savara is get­ting the new year un­der­way with a pub­lic list­ing, cour­tesy of a re­verse merg­er with the zom­bie biotech Mast Ther­a­peu­tics.

Mast had al­ready fall­en in­to pen­ny stock sta­tus last Sep­tem­ber when the com­pa­ny $MSTX was forced to con­cede that its Phase III study of a new drug for sick­le cell dis­ease had failed, leav­ing the San Diego-based biotech with few re­main­ing op­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER